BioXconomy is part of the Informa Connect Division of Informa PLC
Informa PLC
|
ABOUT US
|
INVESTOR RELATIONS
|
TALENT
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
About
Events
Advertise
Stay Updated
Stay Updated
Investment
Related Topics
VC/PE
Seed Funding
IPOs
Recent in
Investment
See All
Money
Investment
Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast
Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast
by
Richard Daverman
Nov 18, 2024
5 Min Read
CMO Summit in Milan, Italy
Investment
IPOs on course for recovery but does biotech need public funding anymore?
IPOs on course for recovery but does biotech need public funding anymore?
by
Dan Stanton
Nov 12, 2024
4 Min Read
Innovation
Related Topics
Hubs
Academic Research
R&D Technology
Recent in
Innovation
See All
coloured pencils
Innovation
Nonprofit looks to bring tomorrow’s science into today’s classrooms
Nonprofit looks to bring tomorrow’s science into today’s classrooms
by
Millie Nelson
Nov 11, 2024
4 Min Read
Asian currency
Innovation
Eyes on Asia: Astellas bags gene therapy, AZ a lipoprotein, and a Japanese incubator
Eyes on Asia: Astellas bags gene therapy, AZ a lipoprotein, and a Japanese incubator
by
Richard Daverman
Oct 21, 2024
4 Min Read
Partnering
Related Topics
Licensing
M&A
Deals
Best Practices
Recent in
Partnering
See All
Shaking hands
Partnering
Picky pharma prone to better proven partners amid dealmaking downturn
Picky pharma prone to better proven partners amid dealmaking downturn
by
Millie Nelson
Nov 19, 2024
3 Min Read
Panelists Anta Gkelou Partner, Sofinnova Partners; Bobby Soni CIO, BioInnovation Institute; Renee Lucander CEO, Calliditas Therapeutics
Partnering
Successful mentorship between investors and CEOs hangs on respect
Successful mentorship between investors and CEOs hangs on respect
Nov 15, 2024
5 Min Read
Business Strategy
Related Topics
Scaling/Commercialization
Growth Strategy
ESG
Outsourcing
Legal
Recent in
Business Strategy
See All
thumbnail
Business Strategy
Build trust by making healthcare fairer and more equitable, say experts
Build trust by making healthcare fairer and more equitable, say experts
by
Millie Nelson
Oct 14, 2024
3 Min Read
Green leaf with sustainability symbol
Business Strategy
The sustainability series: Reflect, rethink, and reform
The sustainability series: Reflect, rethink, and reform
by
Millie Nelson
Oct 11, 2024
14 Min Read
Home
Richard Daverman
Richard Daverman
Editor
Latest from Richard Daverman
Money
Investment
Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast
Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast
by
Richard Daverman
Nov 18, 2024
5 Min Read
Money
Investment
Eyes on Asia: Eyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScript
Eyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScript
by
Richard Daverman
Nov 5, 2024
3 Min Read
All from Richard Daverman
Partnering
Eddingpharm reverse-merger ‘breakthrough’ for Hong Kong stock exchange
Eddingpharm reverse-merger ‘breakthrough’ for Hong Kong stock exchange
Oct 31, 2024
|
3 Min Read
by
Richard Daverman
Innovation
Eyes on Asia: Astellas bags gene therapy, AZ a lipoprotein, and a Japanese incubator
Astellas bags gene therapy, AZ a lipoprotein, and a Japanese incubator
Oct 21, 2024
|
4 Min Read
by
Richard Daverman
Innovation
From east to west: Lilly plans incubators in China and UK
From east to west: Lilly plans incubators in China and UK
Oct 18, 2024
|
2 Min Read
by
Millie Nelson,
Richard Daverman
Hubs
Eyes on Asia: News from Sanofi, Bayer, AZ plus the return of VC?
News from Sanofi, Bayer, AZ plus the return of VC?
Sep 29, 2024
|
2 Min Read
by
Richard Daverman
Hubs
Eyes on Asia: Shinyaku’s $735m DMD deal, Kite turns back in China, and more
Shinyaku’s $735m DMD deal, Kite turns back in China, and more
Sep 23, 2024
|
2 Min Read
by
Richard Daverman
Investment
China biopharma faces a pause; how bad is it?
China biopharma mid-2023 market summary
Sep 21, 2024
|
4 Min Read
by
Richard Daverman
Investment
Eyes on Asia: Eisai $1.5bn pact, OcuMension & Alcon, TYK IPO and more
Eyes on Asia: Eisai $1.5bn pact, OcuMension & Alcon, TYK IPO and more
Sep 18, 2024
|
4 Min Read
by
Richard Daverman
Partnering
Top five Asia biopharma deals: August 2024
Asia biopharma deals: August 2024
Sep 15, 2024
|
4 Min Read
by
Richard Daverman
Partnering
Eyes on Asia: EpimAb sells T-cell, funding for TargetRx, Hygieai on the siRNA march
Eyes on Asia: News from EpimAb, TargetRx, Hygieai
Sep 7, 2024
|
2 Min Read
by
Richard Daverman
Innovation
Eyes on Asia: UCB portfolio sale, Navigator bags $100m, Bora bulks out CDMO biz
Eyes on Asia: UCB portfolio sale, Navigator bags $100m, Bora bulks out CDMO biz
Sep 1, 2024
|
3 Min Read
by
Richard Daverman
Investment
Eyes on Asia: Mulititude out licenses, Huadong bulks up Abs, Merck and Kelun
Eyes on Asia: Multitude out licenses, Huadong bulks up Abs, Merck and Kelun
Aug 25, 2024
|
3 Min Read
by
Richard Daverman
Business Strategy
Webinar
Cracking the code: Mastering biopharma launches in Europe
Register Now
News from APAC
Money
Investment
Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast
Eyes on Asia: GSK’s $300m lupus bet, Pfizer’s $1bn China blast
by
Richard Daverman
Nov 18, 2024
5 Min Read
Money
Investment
Eyes on Asia: Eyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScript
Eyes on Asia: VC hits China, BioStar IPO, and Legend splits from GenScript
by
Richard Daverman
Nov 5, 2024
3 Min Read
Reverse arrow
Partnering
Eddingpharm reverse-merger ‘breakthrough’ for Hong Kong stock exchange
Eddingpharm reverse-merger ‘breakthrough’ for Hong Kong stock exchange
by
Richard Daverman
Oct 31, 2024
3 Min Read
Recommended
Partnering
Novo’s hunt for genetic med tech drove $600m NanoVation pact
Novo’s hunt for genetic med tech drove $600m NanoVation pact
Plenary at BIO-Europe in Munich
Investment
How industry trends are evolving biotech innovation in 2023
2023 industry trends that helped evolve biotech innovation
three member panel on stage
Innovation
‘Data matters most’ in biotech, and AI is here to help
‘Data matters most’ in biotech, and AI is here to help
Subscribe to Our Newsletters
Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.
Stay Updated
